HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

This Study is
No Longer Enrolling

Details
Age

Adult

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 18-2237

More information available at ClinicalTrials.gov: NCT03759379

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers